2 studies found for:    21498393 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NYESO-1 Murine TCR-Gene Engineered Lymphocytes
Conditions: Metastatic Cancers Other Than Melanoma That Express ESO Antigen;   Synovial Sarcoma;   Esophageal;   Heaptoma;   Breast;   Malignant Menigioma
Interventions: Genetic: Anti-NY ESO-1 mTCR PBL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
2 Recruiting A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Adesleukin for Human Papillomavirus-Associated Cancers
Conditions: Cervical Cancer;   Oropharyngeal Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer
Interventions: Drug: Fluderabine;   Drug: Cycolphosphamide;   Biological: Young TIL;   Biological: Aldesleukin

Indicates status has not been verified in more than two years